Novaliq Inc.

Novaliq Inc. is dedicated to leverage the advantages and the potential of the first and only water-free EyeSol® drug delivery technology and its innovative products in development in the U.S. It is a 100% subsidiary of Novaliq GmbH. The Cambridge-based office will be headed by Novaliq’s founder and current chief innovation officer (CIO), Bernhard Günther.

As an emerging leader in the field of ophthalmology, Novaliq is currently pursuing two late-stage clinical trials in the United States:­

1. Novaliq’s ESSENCE phase 2b/3 clinical trial (NCT 03292809) is a pivotal randomized, double-masked, vehicle-controlled, multi-center trial, designed to evaluate the safety, efficacy and tolerability of topical CyclASol® for the treatment of dry eye disease (DED). CyclASol®, has demonstrated better efficacy and tolerability versus current gold-standard Restasis(tm) in a US Phase 2 trial.

2. Novaliq’s SEECASE clinical trial (NCT 03333057) is a phase 2, multi-center, randomized, double-masked, saline-controlled study to evaluate the effect of NOV03 at two different dosing regimens on the signs and symptoms of evaporative DED. NOV03 is potentially the first DED drug treatment addressing Meibomian gland dysfunction (MGD) and evaporative-caused DED.

Contact us:
Novaliq Inc.
Harvard Square One Mifflin Place Suite 400
Cambridge, MA 02138